Clinical trial · Observational
Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies
Fighting Cancer Resistance: Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies
NCT05818020CI-TRIAL-00078307completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is multicentric, observational, and retro- prospective study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biologic | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Sampling of biological material from cancer patients.
- timeFrame
- 3 years
- description
- Sampling size and type of biomaterials, residues in diagnosis and/or clinical activities care, collected by cancer patients and properly stored will include: \- cells and/or tissue fragments during surgical excision (with "open" approach/ laparoscopic/ robotic) of the tumor or parts of the same tissue
- measure
- Sampling of biological material from cancer patients.
- timeFrame
- 3 years
- description
- Sampling size and type of biomaterials, residues in diagnosis and/or clinical activities care, collected by cancer patients and properly stored will include:- blood, cell samples, urine/other biological liquids (saliva, excreted, ascites, pleural fluids, etc.) and faeces,
- measure
- Sampling of biological material from cancer patients.
- timeFrame
- 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of any of the following diseases: 1. breast cancer; 2. melanoma; 3. hepatocarcinoma; 4. gynecological cancer; 5. colorectal cancer; 6. lung cancer. 7. sarcoma; 8. pancreatic tumor; 9. tumor of endocrine glands (thyroid); 10. digestive system tumor (classifying rare ones); 11. urological and/or male genital tumor (classifying rare ones); 12. female genital tumor (classifying rare ones); 13. rare skin tumor; * Signature of the informed consent for the study. * Age 18 years * Biological material leftover from biopsy or surgery, and the residual to the activities of clinical assistance analysis. * No ongoing treatment for oncological diseases at the time of collection. Exclusion Criteria: Patients meeting any of the following criteria are not eligible for the present study: * Patients aged \< 18 years; * Patients who have not signed the informed consent; * Positive history of previous neoplasms (only for "naive" patients); * Positive history of synchronous/metachronous oncological pathologies different from those specified for recruitment (only for "naive" patients); * Ongoing immunosuppressive therapy (only for "naive" patients).
References
Publications (0)
Data not yet available
No reference posted for this study.